Recent Company News

• 03:03 PM ET May 19, 2026
  

  Ipsen announces late-breaking data from study comparing Dysport and Botox in adults with ULS (€157.60, 0.00)

• 04:12 AM ET May 18, 2026
  

  StreetAccount Summary - Trading higher/lower: EU mid-morning

• 01:04 AM ET May 18, 2026
  

  Ipsen initiates new share buy-back program; to purchase an aggregate number of up to 350,000 shares over maximum period of six months. (€166.00, 0.00)

• 11:14 AM ET May 16, 2026
  

  Ipsen presents first corabotase data for moderate-to- severe glabellar lines at the 2026 Scale Symposium in Nashville, TN (€166.00, 0.00)

• 08:12 AM ET May 12, 2026
  

  Rhythm Pharmaceuticals announces new data presentations at the 2026 European Congress of Endocrinology ($87.39, 0.00)

• 01:15 PM ET May 11, 2026
  

  FDA provides safety update on Tazverik, confirms voluntary withdrawal from market (€164.50, 0.00)

• 07:06 PM ET May 05, 2026
  

  Simcere Pharmaceutical Group's SIM0613 for injection receives clinical trial approval from China NMPA (HK$11.72, 0.00)

• 09:19 AM ET Apr 23, 2026
  

  Transcript Intelligence: Ipsen Q1 Sales and Revenue Guidance

• 09:19 AM ET Apr 23, 2026
  

  Transcript Intelligence: Ipsen Q1 Sales and Revenue Themes

• 09:19 AM ET Apr 23, 2026
  

  Transcript Intelligence: Ipsen Q1 Sales and Revenue Q&A